aTyr Pharma Inc. (LIFE)’s Financial Results Comparing With Neurocrine Biosciences Inc. (NASDAQ:NBIX)

aTyr Pharma Inc. (NASDAQ:LIFE) and Neurocrine Biosciences Inc. (NASDAQ:NBIX) compete with each other in the Biotechnology sector. We will analyze and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma Inc. N/A 0.00 34.52M -1.33 0.00
Neurocrine Biosciences Inc. N/A 16.25 N/A 0.18 435.91

Table 1 highlights aTyr Pharma Inc. and Neurocrine Biosciences Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
aTyr Pharma Inc. 0.00% -78.1% -53.6%
Neurocrine Biosciences Inc. 0.00% 5.1% 2.4%

Volatility & Risk

aTyr Pharma Inc. has a 2.42 beta, while its volatility is 142.00%, thus making it more volatile than Standard and Poor’s 500. In other hand, Neurocrine Biosciences Inc. has beta of 1.86 which is 86.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of aTyr Pharma Inc. are 5.4 and 5.4 respectively. Its competitor Neurocrine Biosciences Inc.’s Current Ratio is 8.4 and its Quick Ratio is 8.2. Neurocrine Biosciences Inc. can pay off short and long-term obligations better than aTyr Pharma Inc.

Analyst Recommendations

The Ratings and Recommendations for aTyr Pharma Inc. and Neurocrine Biosciences Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
aTyr Pharma Inc. 0 0 0 0.00
Neurocrine Biosciences Inc. 0 3 6 2.67

Competitively the average price target of Neurocrine Biosciences Inc. is $108.75, which is potential 34.66% upside.

Institutional and Insider Ownership

Roughly 52.6% of aTyr Pharma Inc. shares are held by institutional investors while 0% of Neurocrine Biosciences Inc. are owned by institutional investors. aTyr Pharma Inc.’s share held by insiders are 2.5%. Comparatively, 1.2% are Neurocrine Biosciences Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
aTyr Pharma Inc. -7.27% -11.18% -26.45% -38.19% -84.92% -10.23%
Neurocrine Biosciences Inc. -2.53% -10.56% -11.62% -35.15% -6.23% 10.49%

For the past year aTyr Pharma Inc. had bearish trend while Neurocrine Biosciences Inc. had bullish trend.

Summary

Neurocrine Biosciences Inc. beats on 9 of the 9 factors aTyr Pharma Inc.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.